Investors

Press Releases

 
Press Releases
  Date Title View
Sep 20, 2016
JERSEY CITY, N.J., Sept. 20, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (NASDAQ:SCYX) today announced that the Company will present at the Ladenburg Thalmann Healthcare Conference at the Sofitel New York Hotel on Tuesday, September 27, 2016 at 3:00 p.m. ET. A live webcast will ...
Aug 31, 2016
JERSEY CITY, N.J., Aug. 31, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (NASDAQ:SCYX) today announced that the Company will present at the following upcoming investor conferences: The Baird Global Healthcare Conference at the New York Palace Hotel on Wednesday, September 7, 2016 at 4:20 p.m...
Aug 24, 2016
JERSEY CITY, N.J., Aug. 24, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (Nasdaq:SCYX) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the Company's novel triterpenoid broad-spectrum antifungal agent, SCY-078,  for the treatment of invasive A...
Aug 8, 2016
 Positive Results from Two Phase 2 Studies Confirm Antifungal Clinical Activity of SCY-078  Company is Well Positioned and Capitalized to Advance its Clinical Programs Forward As Planned  JERSEY CITY, N.J., Aug. 08, 2016 (GLOBE NEWSWIRE) -- Drug development compan...
Aug 4, 2016
JERSEY CITY, N.J., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (NASDAQ:SCYX) today announced that the Company will present at the Canaccord Genuity Growth Conference at the InterContinental Boston on Thursday, August 11, 2016 at 2:00 p.m. ET. A live webcast will be available on the ...
Aug 1, 2016
Oral Dose of SCY-078 That Achieves Target Exposure Identified SCY-078 Safe and Well-Tolerated Antifungal Clinical Activity of SCY-078 Further Confirmed JERSEY CITY, N.J., Aug. 01, 2016 (GLOBE NEWSWIRE) -- Drug development company ...
Jul 13, 2016
JERSEY CITY, N.J., July 13, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (Nasdaq:SCYX) today announced that the Company has entered into an Asset Purchase agreement with UK-based Cypralis Limited, a life sciences company focused on the discovery of novel therapeutics based on modulation of peptidyl-prolyl isome...
Jul 6, 2016
JERSEY CITY, N.J., July 06, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (NASDAQ:SCYX) today announced that the Company will present at Cantor Fitzgerald's 2nd Annual Healthcare Conference at Le Parker Meridien New York on Tuesday, July 12, 2016 at 9:00 a.m. ET. A live webcast will...
Jun 21, 2016
JERSEY CITY, N.J., June 21, 2016 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq:SCYX) today announced the pricing of its underwritten public offering of 9,375,000 shares of its common stock and warrants to purchase 4,218,750 shares of its common stock. The shares and warrants are being sold at a public offering price of $2.40 per share sold in t...
Jun 20, 2016
JERSEY CITY, N.J., June 20, 2016 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq:SCYX) today announced that it has commenced an underwritten public offering of shares of its common stock and warrants to purchase shares of its common stock. The company expects to grant the underwriter a 30-day option to purchase additional shares of its common sto...
FirstPrevious
3
... NextLast
= add release to Briefcase